Physician profile
Eyal K Levit
NPI 1801813621
$21,580.71
in general payments reported to CMS, 2019-2025
40 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 85% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,182 · 2020: $1,814 · 2021: $2,085 · 2022: $2,205 · 2023: $4,632 · 2024: $7,041 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,764 · Consulting Fee: $4,330 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,740 · Education: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,764.46 |
| Consulting Fee | $4,330.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,740.00 |
| Education | $460.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $4,186.06 | 2023-2024 | Vtama |
| Amgen INC. | $2,353.71 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $2,238.22 | 2019-2025 | Tremfya, Stelara, Remicade |
| Merz North America, INC. | $1,502.23 | 2019-2023 | Xeomin |
| Pfizer INC. | $1,374.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,172.90 | 2019-2024 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $1,074.45 | 2019-2025 | Blu-U, Odomzo, Winlevi |
| Lilly USA, LLC | $945.42 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $869.23 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $742.69 | 2019-2024 | Erivedge |
| Arcutis Biotherapeutics, INC. | $536.49 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $443.67 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $430.06 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $353.08 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $345.34 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $309.47 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $308.22 | 2022-2025 | Sotyktu |
| Ucb, INC. | $267.75 | 2019-2024 | Bimzelx, Cimzia |
| Abbvie INC. | $246.61 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $235.01 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $234.24 | 2019-2021 | |
| Galderma Laboratories, L.P. | $206.14 | 2019-2022 | |
| Smith+Nephew, INC. | $177.48 | 2019-2023 | Regranex, Collagenase Santyl |
| Biofrontera INC. | $176.76 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Celgene Corporation | $160.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $123.43 | 2025 | Acthar |
| Botanix Sb INC | $109.46 | 2025 | Sofdra |
| Almirall LLC | $98.20 | 2019-2021 | |
| Dermira, INC. | $71.08 | 2019-2021 | |
| Organon LLC | $54.13 | 2025 | Vtama |
| Journey Medical Corporation | $37.22 | 2024-2025 | |
| Allergan, INC. | $34.35 | 2019-2020 | |
| Kyowa Kirin, INC. | $24.90 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.36 | 2023 | Spevigo |
| Paratek Pharmaceuticals, INC. | $22.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.51 | 2020 | |
| Sandoz INC. | $19.74 | 2020 | |
| Organogenesis INC. | $19.72 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $17.54 | 2019 | |
| Epi Health, LLC | $14.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eyal Levit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.